FUNDING OPPORTUNITY DETAILS AND IMPORTANT DATES

Program Name: Geoff Ogram Memorial Research Grant
Grant Status: Accepting applications
Deadline Date: June 28, 2019 11:59 EST
Anticipated Notice of Decision: July 26, 2019
Funding Start Date: September 1, 2019

The Geoff Ogram Memorial Research Grant (GOMRG) supports advancement in lung cancer research programs that are anywhere in the continuum from basic, high impact discovery to translational work of direct relevance to the clinic and beyond. The goal of the GOMRF program is to provide a mechanism for scientists to study innovations and accelerate the application of new knowledge relating to the early detection of lung cancer and the etiology of lung cancer in different demographics and populations. Applications are encouraged from, but not limited to, the areas of biomedical, clinical, health services, social, and population health research.

The overall goal of the GOMRG is to reduce the burden of lung cancer and optimize patient care. It is not intended to support awareness programs and is not intended to solely support research infrastructure.

FUNDS AVAILABLE:
One competition per year - one $25,000 (CDN) grant will be awarded. Funding will be provided to support the direct costs of a defined research program, including supplies, expenses*, wages and equipment associated with the proposed work. Indirect costs** are not eligible expenses.

OBJECTIVES:
This grant provides a research opportunity focused in:
1. Research into early detection lung cancer methodologies, including but not limited to screening OR blood based testing. Early detection research among those not meeting current screening criteria would be welcomed.
2. Research into the etiology of lung cancer of different populations and demographics, specifically light ex-smokers or non-smokers.

Proposals with direct practical relevance to Canadians with lung cancer will be prioritized.

* This grant follows the convention of acceptable expenses as outlined by the Canadian Institute of Health Research (CIHR) and Natural Sciences Engineering Research Council (NSERC) http://www.nserc-crsng.gc.ca/Professors-Professeurs/FinancialAdminGuide-GuideAdminFinancier/FundsUse-UtilisationSubventions_eng.asp. In addition, this grant may not be used to cover costs associated with conference travel or publication.

** Indirect costs of research are expenditures incurred in the conduct of research that are not readily or effectively traceable to specific expense. These may include but are not limited to: overhead, infrastructure and space maintenance, support services for research, including central research and financial service, environmental health and safety resources, meeting regulatory certification requirements, and providing key resources such as library and computer information services.
APPLICATION PROCESS:
The application process consists of a Letter of Intent, which requires the following:
1. A summary of the proposed research (maximum of 2 pages, single-spaced, maximum of 4 supporting figures or tables).
2. An impact statement which addresses the potential of the project to exert a sustained, powerful, influence on the research field(s) involved and how this work will reduce lung cancer incidence, reduce mortality, or improve patient quality of life. The statement should explicitly describe how the project will promote major advancement in lung cancer research, aiming to accelerate and focus the knowledge gained from scientific findings, in the short- to medium-term, into outcomes such as optimized patient care, improved treatment, or reduced burden.
3. A public, non-scientific summary (up to 500 words).
4. Budget – including justification for supplies, equipment, and personnel associated with the research project. This must include the number of personnel required to complete the work, a description of their experience and/or education level, and their commitment to the project.
5. The names of the investigator(s) and CVs for the PI and any co-PIs.
6. A statement of support from the applicant’s institution with confirmation that the proposed research is feasible in that institution.

REVIEW PROCESS AND EVALUATION
Applications will be reviewed by a panel of experts consisting of a subcommittee drawn from members of the Lung Cancer Canada Medical Advisory Committee.

The application submission process has two steps:
1. Fill out the application form online: http://bit.ly/GORMG.
2. Submit the form with a pdf or docx attachment containing all application components as one file.

CONDITIONS OF FUNDING
Successful applicants funded through this opportunity and any other persons working on the project must comply fully with the Lung Cancer Canada Funding Policies. Policies and guidelines cover areas such as Applicant Responsibilities, Official Languages policy, Access to Information and Privacy Acts, and Acknowledgement of Lung Cancer Canada’s Support.

The award must be accepted within 15 working days of the date of offer or the award will be cancelled and offered to the next fundable applicant.

The successful applicant must:
- Begin their award within 6 months of the earliest possible start date stated in this funding opportunity.
- Complete the research within one year of the start date or provide an annual written update if this is a multi-year project.
- Submit a final results report to Lung Cancer Canada within 3 months of the completion date.
- Contribute a 500 word document for publication within Lung Cancer Canada’s digital and print forums.
- Organize and host a community event to increase lung cancer awareness. A broad scope of event types is acceptable to fulfill this criteria (e.g. lung cancer awareness day at hospital or university health centre, social media campaign, public school awareness event).
Present the research findings at a regional or national conference with a lung cancer focus. Conferences include, but are not limited to, Ontario Thoracic Cancer Conference, Canadian Lung Cancer Conference, Atlantic Canada Thoracic Oncology Conference, CAMO or CARO or CATS annual meetings (Canadian Association of: Medical Oncologists, Radiation Oncologists, Thoracic Surgeons). Local level events such as hospital/university student research days may also be considered. Choice of conference/event must be approved by the Lung Cancer Canada Medical Advisory Committee. The investigator is responsible for all expenses related to conference/event attendance.

Lung Cancer Canada recognizes that this research opportunity may fit within a larger research project and will disseminate the results in a public forum only with written consent.

COMMUNICATION REQUIREMENTS
Award recipients are required to acknowledge Lung Cancer Canada and any partners in any communication or publication related to the project. The contributing partners will be identified on the decision letter.

CONTACT INFORMATION
For questions about this initiative, please contact Lung Cancer Canada at: Telephone: 416.785.3439 / 1.888.445.4403 or Email: info@lungcancercanada.ca.

OFFICIAL LANGUAGES
Lung Cancer Canada is committed to promotion of and compliance to the applicable parts of the Official Languages Act. As such, Lung Cancer Canada encourages applicants to submit proposals in the Official Language of their choice and commits to ensuring high quality review of applications submitted in either Official Language. In addition, applicants are encouraged to consider the inclusion of Official Languages and Official Language Minority Communities in their research where appropriate.

ACCESS TO INFORMATION ACT AND PRIVACY ACT, AND THE PERSONAL INFORMATION PROTECTION AND ELECTRONIC DOCUMENTS ACT (PIPEDA)
All personal information collected by Lung Cancer Canada about applicants is used to review applications, to recruit reviewers, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by Lung Cancer Canada may be shared as described in the Conflict of Interest and Confidentiality Policy of the Federal Research Funding Organizations.

Lung Cancer Canada is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in Lung Cancer Canada premises including, without limitation, cost-sharing agreements related to this funding opportunity and all matters pertaining thereto.

While respecting the application of the Privacy Act to federal entities, all signing parties involved in a collaborative agreement will also be bound by the Personal Information Protection and Electronic Documents Act (PIPEDA). All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under collaborative agreements related to the Funding opportunity will be collected, used and disclosed in compliance with the PIPEDA.